Who we are
We believe that clinical adoption of psychedelic therapies represents an opportunity to reduce human suffering on an unprecedented scale.
The Psychedelic Action Task Force is a clinician and scientist-led coalition working to redress the UK mental health crisis and provide solutions to its severe social and economic repercussions, namely, through the democratisation of access to psychedelic treatments in respect of which there is sufficient evidence of both safety and efficacy, whilst also supporting critical research, including with respect to palliative care.
Founded in 2024 by Prof. David Nutt and Alex Adams, Psychedelic Action will be advocating for evidence-based drug policy reform, conducting a revaluation of current clinical paradigms, and developing a roadmap to facilitate the integration of psychedelic therapy into the UK healthcare system, including the training of clinicians and therapists.
Join our clinical working group (CWG)
Our CWG comprises world-leading psychedelic researchers and clinicians, including from Imperial College London, King’s College London, and The Maudsley, along with experts in addiction, medical cannabis and ketamine treatment.
If you are a UK-based clinician or scientist and would like to be involved in our work, or be part of the conversation on how to transform healthcare, please fill out the following form and we will be in touch in due course:
Background
Psychedelic Action has been formed in the belief that current legislation, which prohibits the clinical use of psychedelic compounds (including MDMA, LSD, psilocybin and DMT) outside the context of research trials specifically licensed by the Home Office, is unjustifiable.
After more than 50 years of prohibition, criminalisation and stigmatisation, science is finally showing that certain psychedelics when used according to established protocols in clinical settings are not usually dangerous or harmful.
Instead, when used according to tested, safe and ethical guidelines, they are the next revolution in mental health treatment.
In the context of a growing mental health crisis and lack of adequate tools to treat a plethora of psychiatric conditions, including PTSD, depression, anxiety, and addiction, the potential of psychedelic therapies to treat such conditions - for which there is strong data in support - can no longer be ignored.
The UK is failing patients most at need, enduring the severe economic consequences of the mental health crisis, and missing an opportunity to be a pioneering hub for mental health treatment.
We believe the need for systemic change is now a moral imperative and that this should be led by clinicians and scientists, free from commercial and political influence.